Wells Fargo raised the firm’s price target on Wave Life Sciences (WVE) to $29 from $16 and keeps an Overweight rating on the shares. The firm thinks INHBE/Activin-E knockdown has emerged as an exciting target for obesity, and that there’s a path for WVE-007 to emerge with better dosing, better tolerability, and muscle sparing vs GLP1.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences price target raised to $30 from $16 at Citi
- Closing Bell Movers: Toll Brothers slips 4% after Q4 earnings miss
- Wave Life Sciences upgraded to Outperform at RBC on rapid WVE-007 effect
- Wave Life Sciences upgraded to Outperform from Sector Perform at RBC Capital
- Morgan Stanley sees positive readthrough to Arrowhead pipeline from Wave data